The private sector added 86,000 jobs in October, surpassing economists' expectations of 69,000 new positions, according to ADP. Key industries driving job growth included trade, transportation, utilities, education, and health services. Employers of all sizes contributed to hiring, with large businesses adding 24,000 jobs and smaller firms also showing gains. This robust hiring suggests rising earnings growth and positive momentum ahead of the official Labor Department report expected Friday, which forecasts a smaller gain of 65,000 jobs and steady unemployment at 4.2%.
Private sector job additions in October reached 86,000, surpassing expectations, as of Nov 05, 2026 01:21 WIB. For readers following US stocks on Pluang, here is the market snapshot: out of 150 priced stocks, 121 rose and 29 fell. Notable movers include XYZ (Block Inc) at USD 88.07 with a 15.93% increase, OPEN (Opendoor Technologies Inc) at USD 2.00 with a 14.94% rise, and JBLU (JetBlue Airways Corporation) at USD 3.62 with a 13.84% gain.
Goldman Sachs Group, Inc. disclosed that it briefly held a combined stake exceeding 3% in Ontex Group NV shares as of October 27, 2026, with 566,115 voting rights and 1,965,157 financial instruments. However, by October 28, 2026, their combined posit...
BNP Paribas announced its monthly declaration of voting rights and shares as of October 31, 2026. The bank reported a total of 1,101,600,607 shares and an equal number of voting rights. This update is part of regulatory compliance under French commer...
Ontex disclosed that Goldman Sachs Group, Inc. crossed the 3% ownership threshold in Ontex shares on October 27, 2026, holding a combined total of 3.07% including voting rights and financial instruments. However, the next day, October 28, 2026, Goldm...
Neion Bio has appointed John A. Maga, Ph.D., as Head of Biologics and CMC to lead the development of biologic medicines using its Raptor platform, which produces proteins in transgenic chicken eggs. Maga brings over 25 years of biopharmaceutical expe...
The National Advertising Division (NAD) recommended that Good Life Meds discontinue claims about health benefits and personalization for its compounded Tirzepatide+ weight loss products after a challenge by Eli Lilly. NAD found that Good Life lacked ...
